Becton Dickinson’s Immune Function Test for COVID-19 Gains CE Mark
Becton Dickinson (BD) has received a CE mark for its BD Multitest six-color, T-cell, B-cell and natural-killer cells (TBNK) reagent for assessing T-cell subtypes in COVID-19 patients.
The reagent is used with the company’s FACSLyric and FACSCanto II cytometers to measure COVID-19 patient T-cell subsets, which play an important role in neutralizing the coronavirus. The test was previously cleared to assess immune function in HIV patients.
The product’s availability for COVID-19 patients “is an important step in helping clinicians better understand how patient immune systems are responding to COVID-19 infection,” said Puneet Sarin, BD’s president of biosciences.